Cargando…
Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series
Current treatment options for visceral leishmaniasis have several drawbacks, and clinicians are confronted with an increasing number of treatment failures. To overcome this, the Drugs for Neglected Diseases initiative (DNDi) has invested in the development of novel antileishmanial leads, including a...
Autores principales: | Van den Kerkhof, Magali, Leprohon, Philippe, Mabille, Dorien, Hendrickx, Sarah, Tulloch, Lindsay B., Wall, Richard J., Wyllie, Susan, Chatelain, Eric, Mowbray, Charles E., Braillard, Stéphanie, Ouellette, Marc, Maes, Louis, Caljon, Guy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305145/ https://www.ncbi.nlm.nih.gov/pubmed/34210040 http://dx.doi.org/10.3390/microorganisms9071408 |
Ejemplares similares
-
Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance
por: Van den Kerkhof, M., et al.
Publicado: (2020) -
In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series
por: Van den Kerkhof, M., et al.
Publicado: (2018) -
Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum
por: Hendrickx, Sarah, et al.
Publicado: (2017) -
Interferon Alpha Favors Macrophage Infection by Visceral Leishmania Species Through Upregulation of Sialoadhesin Expression
por: Van Bockstal, Lieselotte, et al.
Publicado: (2020) -
Experimental Strategies to Explore Drug Action and Resistance in Kinetoplastid Parasites †
por: Van den Kerkhof, Magali, et al.
Publicado: (2020)